Here we describe a case of BO secondary to TEN, which presented with a favorable clinical outcome. This is the first case reported in adults in Brazil, according to searches on the PubMed database.

BACKGROUND In adults, erythema multiforme (EM) is thought to be mainly related to herpes infection and Stevens–Johnson syndrome (SJS ... effect has been reported in patients with toxic epidermal ...

Stevens-Johnson syndrome (SJS), also called erythema multiforme major, is a systemic disease mostly involving the skin and mucous membranes. The cutaneous lesions are those of erythema multiforme ...

and the patient was clinically unimproved. At this time the diagnosis was revised to toxic erythema multiforme bullosum (Stevens-Johnson syndrome), and it was thought that sulfonamide therapy ...

Tributes quickly began pouring in from fans and colleagues, including fellow director Steven Spielberg, who cast Lynch in his 2022 film "The Fabelmans." Lynch portrayed director John Ford ...

Steven Spielberg, Ron Howard and more have paid tribute to David Lynch, the visionary director behind “Twin Peaks” and “Blue Velvet” who died at 78 years old. “I loved David’s films. ...

Supported by operational growth of 6.7%, Johnson & Johnson (JNJ, Financials) reported a 5.3% rise in fourth-quarter revenues to $22.5 billion. With operational growth of 5.9% except for COVID-19 ...

Johnson & Johnson (JNJ) beat on fourth quarter and full-year 2024 results, but its stock traded down on Wednesday morning to about $143 per share. Several negative impacts were highlighted in the ...

Johnson & Johnson (NYSE:JNJ) is scheduled to announce Q4 earnings results on Wednesday, January 22nd, before market open. Analysts expect a profit per share of $2.02, which is a decline of 11.8% ...

Bryan Johnson, a tech entrepreneur, has stopped using rapamycin, a drug not approved for anti-aging by the FDA, following concerns it may have aged him and caused infections. Johnson experienced ...

Gabby Jones / Bloomberg / Getty Images Johnson & Johnson is scheduled to report fourth-quarter earnings Wednesday morning, with analysts expecting sales and profits to grow year-over-year.